Pathogen patterns in viral ARDS on V-V ECMO: a single-center experience - Summary - MDSpire

Pathogen patterns in viral ARDS on V-V ECMO: a single-center experience

  • By

  • Jannis Krais

  • Matthias Lubnow

  • Alois Philipp

  • Maik Foltan

  • Florian Geismann

  • Christoph Fisser

  • Florian Hitzenbichler

  • Bernd Salzberger

  • Stilla Bauernfeind

  • Barbara Schmid

  • Dirk Lunz

  • Johannes Steinmann

  • Christoph Eissnert

  • Martin Kieninger

  • Walter Petermichl

  • Roland Schneckenpointner

  • Alexander Dietl

  • Lars S. Maier

  • Bernhard Graf

  • Thomas Müller

  • Clemens Wiest

  • July 15, 2026

Share

Objective:

To characterize and compare the prevalence, timing, and microbiological spectrum of superinfections in viral ARDS caused by SARS-CoV2 or influenza in a large cohort of V-V ECMO-treated patients.

Approach:
  • Microbiological Testing: COVID-19 patients underwent extensive microbiological diagnostics via bronchoalveolar lavage (BAL), while influenza patients had microbiological testing limited to ICU admission and clinical deterioration.
Key Findings:
  • Reported VAP incidence in COVID-19 patients on V-V ECMO is as high as 86%, predominantly caused by Enterobacteriaceae, with a high prevalence (57%) of extended spectrum beta-lactamase (ESBL) producers.
Interpretation:

Detailed data on superinfections in viral ARDS patients on V-V ECMO are limited.

Limitations:
  • Retrospective nature of the study may introduce biases.
  • Less frequent microbiological testing in influenza patients compared to COVID-19 patients.
Conclusion:

The study provides insights into the prevalence and types of superinfections in patients with viral ARDS requiring V-V ECMO.

Original Source(s)

Pathogen patterns in viral ARDS on V-V ECMO: a single-center experience

  • by Jannis Krais, Matthias Lubnow, Alois Philipp, Maik Foltan, Florian Geismann, Christoph Fisser, Florian Hitzenbichler, Bernd Salzberger, Stilla Bauernfeind, Barbara Schmid, Dirk Lunz, Johannes Steinmann, Christoph Eissnert, Martin Kieninger, Walter Petermichl, Roland Schneckenpointner, Alexander Dietl, Lars S. Maier, Bernhard Graf, Thomas Müller, Clemens Wiest

  • July 15, 2026

Related Content

Integrated transcriptomic and immune analysis reveals distinct mitochondrial and immune signature in COVID-19 ARDS requiring invasive mechanical ventilation

Symptom burden, lung function, exercise tolerance and inflammation in patients post COVID-19: results from the prospective COVID-19 Chronic Morbidity (CCHROMO) study

JinHuangJieDu (JHJD) formula attenuates SARS-CoV-2 infection by interrupting RBD-ACE2 binding and HIF-1α-dependent inflammation